INCY

Incyte Corporation

Price

$97.69

return (12m)

p/e

16.30

p/bv

4.15

DIVIDEND YIELD

0.00%

INCY price

Incyte

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment INCY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals INCY

Valuation

P/E

16.30

Sector -4.15

Industry -4.15

P/BV

4.15

Sector 2.06

Industry 2.06

P/Revenue (PSR)

4.35

Sector -4.16

Industry -4.16

EV/EBITDA

52.51

Sector -241.86

Industry -241.86

EV/EBIT

56.14

Sector -671.75

Industry -671.75

P/EBITDA

12.47

Sector -4.30

Industry -4.30

P/EBIT

13.14

Sector -4.35

Industry -4.35

P/Total Assets

3.18

Sector 1.46

Industry 1.46

P/Net Current Assets

6.19

Sector -12.67

Industry -12.67

P/Working Capital

5.84

Sector -12.58

Industry -12.58

EPS

7.19

Sector -2.19

Industry -2.19

BVPS

28.26

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

92.48%

Sector 36.44%

Industry 36.44%

EBITDA Margin

28.91%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

27.04%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

27.05%

Sector -38.78%

Industry -38.78%

Net Profit Margins

26.71%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

25.46%

Sector -67.01%

Industry -67.01%

ROA

19.51%

Sector -66.28%

Industry -66.28%

ROIC

39.63%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.68

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-10.91

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

-11.67

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.71

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.77

Sector 0.42

Industry 0.42

Liabilities/Assets

0.23

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

12.41%

Sector -

Industry -

5Y Earnings CAGR

8.58%

Sector -

Industry -

FAIR VALUE OF Incyte ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$97.69

Fair Value

$67.61

Upside Return potential.

-30.79%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals INCY

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
INCY Incyte Corporation	$97.69	71.78%	0.00%	16.30	4.15	25.46%	26.71%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INCY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Incyte

Incyte Corporation

Average Investor10 user rating

4.0 (0 people)

States of America

35 years

Founded: 1991

1993

Time since IPO - 33 years

1.773

Employees

Incyte Corporation (States of America) is listed on the Nasdaq and has a market capitalization of $23.34 billion, with shareholders equity totaling $5.62 billion.

The company employs approximately 1.773 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Incyte Corporation reported $5.36 billion in revenue, generating net income of $1.43 billion.

Key financial metrics include a P/E ratio of 16.30, a price-to-book (P/B) ratio of 4.15, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INCY.

Market cap

$23.34 billion

Net worth

$5.62 billion

$5,622,850,000.00

Assets

$7.34 billion

$7,339,110,000.00

Total Shares Outstanding

199.00 million

199,000,000

Average Daily Trading Volume

$1.79 million

$1,786,430.54

Sector

Healthcare

Industry

Biotecnologia

INCY

revenue by Business Segment Incyte

INCY revenue and profits

Financial Results INCY

DRAG THE FRAME TO SEE MORE DATA

INCY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14